203 related articles for article (PubMed ID: 28342027)
41. Development of Targeted Alpha Particle Therapy for Solid Tumors.
Tafreshi NK; Doligalski ML; Tichacek CJ; Pandya DN; Budzevich MM; El-Haddad G; Khushalani NI; Moros EG; McLaughlin ML; Wadas TJ; Morse DL
Molecules; 2019 Nov; 24(23):. PubMed ID: 31779154
[TBL] [Abstract][Full Text] [Related]
42. Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.
Miederer M; Scheinberg DA; McDevitt MR
Adv Drug Deliv Rev; 2008 Sep; 60(12):1371-82. PubMed ID: 18514364
[TBL] [Abstract][Full Text] [Related]
43. A review of recent advancements in Actinium-225 labeled compounds and biomolecules for therapeutic purposes.
Hassan M; Bokhari TH; Lodhi NA; Khosa MK; Usman M
Chem Biol Drug Des; 2023 Nov; 102(5):1276-1292. PubMed ID: 37715360
[TBL] [Abstract][Full Text] [Related]
44. Evaluation of the Effect of Chelating Arms and Carrier Agents on t he Radiotoxicity of TAT Agents.
Farzipour S; Shaghaghi Z; Raeispour M; Alvandi M; Jalali F; Yazdi A
Curr Radiopharm; 2023; 16(1):2-22. PubMed ID: 35538822
[TBL] [Abstract][Full Text] [Related]
45. Clinical trials of targeted alpha therapy for cancer.
Allen BJ
Rev Recent Clin Trials; 2008 Sep; 3(3):185-91. PubMed ID: 18782076
[TBL] [Abstract][Full Text] [Related]
46. Protein targeting constructs in alpha therapy.
Olafsen T; Elgqvist J; Wu AM
Curr Radiopharm; 2011 Jul; 4(3):197-213. PubMed ID: 22201709
[TBL] [Abstract][Full Text] [Related]
47. Astatine-211 Radiopharmaceuticals; Status, Trends, and the Future.
Rabiei M; Asadi M; Yousefnia H
Curr Radiopharm; 2024; 17(1):7-13. PubMed ID: 37937552
[TBL] [Abstract][Full Text] [Related]
48. Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle.
Dekempeneer Y; Keyaerts M; Krasniqi A; Puttemans J; Muyldermans S; Lahoutte T; D'huyvetter M; Devoogdt N
Expert Opin Biol Ther; 2016 Aug; 16(8):1035-47. PubMed ID: 27145158
[TBL] [Abstract][Full Text] [Related]
49. An overview of targeted alpha therapy.
Kim YS; Brechbiel MW
Tumour Biol; 2012 Jun; 33(3):573-90. PubMed ID: 22143940
[TBL] [Abstract][Full Text] [Related]
50. Bismuth chelation for targeted alpha therapy: Current state of the art.
Franchi S; Di Marco V; Tosato M
Nucl Med Biol; 2022; 114-115():168-188. PubMed ID: 35753940
[TBL] [Abstract][Full Text] [Related]
51. Recent Achievements about Targeted Alpha Therapy-Based Targeting Vectors and Chelating Agents.
Farzipour S; Shaghaghi Z; Abbasi S; Albooyeh H; Alvandi M
Anticancer Agents Med Chem; 2022; 22(8):1496-1510. PubMed ID: 34315393
[TBL] [Abstract][Full Text] [Related]
52. Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49.
Kennel SJ; Brechbiel MW; Milenic DE; Schlom J; Mirzadeh S
Cancer Biother Radiopharm; 2002 Apr; 17(2):219-31. PubMed ID: 12030116
[TBL] [Abstract][Full Text] [Related]
53. Tumour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer.
Allen BJ; Raja C; Rizvi S; Song EY; Graham P
Phys Med Biol; 2007 Jul; 52(13):L15-9. PubMed ID: 17664565
[TBL] [Abstract][Full Text] [Related]
54. Targeted alpha therapy with
Ackerman NL; de la Fuente Rosales L; Falzone N; Vallis KA; Bernal MA
Phys Med; 2018 Jul; 51():91-98. PubMed ID: 29807854
[TBL] [Abstract][Full Text] [Related]
55. Engineered liposomes for potential alpha-particle therapy of metastatic cancer.
Sofou S; Thomas JL; Lin HY; McDevitt MR; Scheinberg DA; Sgouros G
J Nucl Med; 2004 Feb; 45(2):253-60. PubMed ID: 14960644
[TBL] [Abstract][Full Text] [Related]
56. Radioimmunotherapy with α-particle-emitting radionuclides.
Seidl C
Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
[TBL] [Abstract][Full Text] [Related]
57. Radioimmunotherapy of human tumours.
Larson SM; Carrasquillo JA; Cheung NK; Press OW
Nat Rev Cancer; 2015 Jun; 15(6):347-60. PubMed ID: 25998714
[TBL] [Abstract][Full Text] [Related]
58. Addendum to: Basic immunology of antibody targeted radiotherapy: in regard to Wong (Int J Radiat Oncol Biol Phys 2006;66: S8-S14).
Allen BJ
Int J Radiat Oncol Biol Phys; 2007 May; 68(1):314. PubMed ID: 17448888
[No Abstract] [Full Text] [Related]
59. Development of
Robertson AKH; Ramogida CF; Schaffer P; Radchenko V
Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444
[TBL] [Abstract][Full Text] [Related]
60. ²¹³Bi-anti-EGFR radioimmunoconjugates and X-ray irradiation trigger different cell death pathways in squamous cell carcinoma cells.
Pickhard A; Piontek G; Seidl C; Kopping S; Blechert B; Mißlbeck M; Brockhoff G; Bruchertseifer F; Morgenstern A; Essler M
Nucl Med Biol; 2014 Jan; 41(1):68-76. PubMed ID: 24210808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
